Onconova Therapeutics, Inc.

Equities

ONTX

US68232V8019

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.01 USD +4.12% Intraday chart for Onconova Therapeutics, Inc. +21.69% +35.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma CI
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s CI
Transcript : Onconova Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Posts Q3 Revenue $57,000 MT
Onconova Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer CI
Transcript : Onconova Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Reports Q2 Revenue $57,000, vs. Street Est of $0.07M MT
Onconova Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma CI
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade CI
Onconova Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Onconova Therapeutics, Inc., Q1 2023 Earnings Call, May 15, 2023
Onconova Therapeutics Doses First Patient in Clinical Trial of Endometrial Cancer Combination Therapy MT
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer CI
North American Morning Briefing : Stock Futures -2- DJ
Top Midday Gainers MT
HC Wainwright Upgrades Onconova Therapeutics to Buy From Neutral, Price Target is $11 MT
Onconova Therapeutics Chief Medical Officer Mark Gelder Dies Unexpectedly MT
Onconova Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Onconova Therapeutics, Pangea Biomed Collaborate to Identify Biomarkers of Response to Rigosertib MT
Onconova Therapeutics, Inc. and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Transcript : Onconova Therapeutics, Inc., Q4 2022 Earnings Call, Mar 16, 2023
Onconova Therapeutics, Inc. Presents Preclinical Data Characterizing Rigosertib’s Mechanisms CI
Chart Onconova Therapeutics, Inc.
More charts
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing products for patients with cancer. It has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. It has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. It is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.01 USD
Average target price
8.333 USD
Spread / Average Target
+725.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Onconova Therapeutics, Inc. - Nasdaq
  4. News Onconova Therapeutics, Inc.
  5. Onconova Therapeutics : Increases Enrollment in Study of Breast Cancer Treatment in China